Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
JERSEY CITY, N.J., March 07, 2017 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.
A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781.591.3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
